RESEARCH MONOGRAPH · KDC-MN-094

Setmelanotide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

74/100

Selective MC4R agonist with FDA approval for rare monogenic obesity, the best-characterized member of its class

Setmelanotide (Imcivree) is Rhythm Pharmaceuticals' selective MC4R agonist, developed specifically for monogenic obesity syndromes caused by loss-of-function mutations in upstream melanocortin pathway genes (POMC, PCSK1, LEPR). It received FDA approval in 2020 for these specific indications, making it the most clinically validated MC4R-selective compound on the market.

What we like is the precision medicine story. In patients with POMC, PCSK1, or LEPR deficiency, the endogenous alpha-MSH signal to MC4R is absent or impaired, and the resulting hyperphagia and obesity are essentially MC4R-deficient phenotypes. Setmelanotide bypasses the upstream block by directly agonizing MC4R, restoring satiety signaling. The phase 3 trials (Clement 2020, Lancet) showed dramatic weight loss in these specific patient populations (greater than 25% BMI reduction in POMC deficiency), with effect sizes that are essentially unprecedented for the underlying conditions. This is genuinely important pharmacology for a small group of patients.

What we dont like: outside the approved monogenic indications, the effect size is much smaller. Phase 2 trials in common polygenic obesity showed only modest weight loss (a few percent over placebo), which makes biological sense because most polygenic obesity isn't caused by MC4R signaling deficiency. The drug is doing exactly what its mechanism predicts: it's selectively useful in patients with upstream MC4R pathway deficits, not in general obesity. The side effect profile (hyperpigmentation from residual MC1R activation, nausea, injection site reactions, occasional psychiatric effects) is real but generally tolerable.

Sourcing for research-grade material is improving but still limited. Setmelanotide is a cyclic peptide (8 residues with a lactam bridge) and synthesis is well-established at scale; reputable peptide vendors produce HPLC pure material. Verify mass spec for the cyclization and watch for the specific Arg residue stereochemistry which is essential for MC4R selectivity over MC1R.

For research on MC4R pharmacology and obesity genetics, setmelanotide is the reference MC4R-selective compound and the FDA-approved indication provides hard clinical validation. The selective MC4R agonism with minimal MC1R activation makes it cleaner than Melanotan II for mechanism work. Genuinely important compound for a specific patient population and a useful pharmacology tool.

Evidence: 82
Mechanism: 88
Reliability: 80
Safety: 70
Sourcing: 65
Value: 55
Signal: 78
Staying power: 75

Plain-language summary Intrigue 84 / 100

Setmelanotide, sold as Imcivree, is a selective MC4 receptor agonist approved by the FDA for genetic obesity caused by mutations in the leptin-melanocortin pathway. It is one of the first targeted obesity drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective MC4 receptor agonist

An FDA-approved (2020) selective MC4 receptor agonist (Imcivree) for genetic obesity disorders (POMC, LEPR, PCSK1 deficiency).

Abstract

Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; molecular weight 1117.34) is a selective MC4 receptor agonist developed by Rhythm Pharmaceuticals and approved by the FDA in 2020 for chronic weight management in adults and children aged 6 years and older with obesity due to proopiomelanocortin (POMC), leptin receptor (LEPR), or PCSK1 deficiency. The compound is also approved for Bardet-Biedl syndrome obesity (2022). Mechanism is selective MC4 agonism in the hypothalamus, restoring downstream signaling in the leptin-melanocortin pathway disrupted by upstream genetic defects. The drug produces clinically meaningful weight loss in the genetically defined responder populations but minimal effect in non-genetic obesity. Pharmacokinetics: subcutaneous administration; plasma half-life approximately 11 hours. Reported research dose ranges in the literature are around 2 to 3 mg subcutaneous.

Mechanism of action

Selective MC4 receptor agonist; restores melanocortin pathway signaling in genetic obesity disorders.

Reported research dose ranges

2 to 3 mg SC (reported research dose ranges in the literature).

References

Clement K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency. Lancet Diabetes Endocrinol 2020.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-094

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Setmelanotide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs